FHTX — Foghorn Therapeutics. Income Statement
0.000.00%
Last trade - 00:00
- $254.97m
- $20.91m
- $34.16m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0.43 | 1.32 | 19.2 | 34.2 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 51.1 | 69.2 | 103 | 136 | 142 |
Operating Profit | -51.1 | -68.8 | -102 | -117 | -108 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -51.1 | -68.8 | -101 | -109 | -94.2 |
Provision for Income Taxes | |||||
Net Income After Taxes | -51.1 | -68.8 | -101 | -109 | -98.4 |
Net Income Before Extraordinary Items | |||||
Net Income | -51.1 | -68.8 | -101 | -109 | -98.4 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -51.1 | -68.8 | -101 | -109 | -98.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -4.7 | -1.86 | -2.69 | -2.62 | -2.34 |
Dividends per Share |